discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new ...

discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Since G4s are also implicated in other diseases such as Alzheimer’s Disease, this discovery may broaden the impact of such treatments beyond Parkinson’s Disease. These findings were published in the ...

According to the new study, patients with a slow progression ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a ...